RGX-111

Schall Law Firm seeks investors in $RGNX securities fraud class action over allegedly misleading statements about RGX-111 clinical trial data.

REGENXBIO faces class action over alleged misleading statements about RGX-111 gene therapy. Investors who bought stock between February 2022 and January 2026 may seek compensation.

REGENXBIO faces class action lawsuit over RGX-111 gene therapy trial disclosures. Lead plaintiff deadline is April 14, 2026.

REGENXBIO faces securities lawsuit alleging misleading statements about RGX-111 gene therapy. Lead plaintiff deadline extended to April 14, 2026.

REGENXBIO faces class action lawsuit alleging false statements about gene therapy RGX-111's safety and efficacy. Investors must act by April 14, 2026 deadline.

REGENXBIO faces class action lawsuit alleging executives made false statements about RGX-111 gene therapy's efficacy and safety, seeking shareholder damages.

Class action lawsuit filed against REGENXBIO for allegedly making false statements about gene therapy safety and efficacy while withholding adverse trial information from investors.

REGENXBIO faces securities fraud lawsuit over alleged misrepresentations about RGX-111's safety and efficacy. A CNS tumor discovery contradicted prior investor statements, causing shareholder losses.

REGENXBIO faces securities class action alleging false statements about RGX-111 gene therapy program and clinical trial outcomes. Investors from February 2022-January 2026 may recover damages.

REGENXBIO faces class action lawsuit over allegedly false safety disclosures for gene therapy RGX-111. FDA clinical hold triggered 17.8% stock drop after adverse trial findings.

REGENXBIO faces securities lawsuit over alleged false statements about gene therapy safety. Investors have until April 14 deadline to join class action after FDA clinical hold.

REGENXBIO faces class action lawsuit alleging false statements about RGX-111 gene therapy trial results, covering securities purchased between February 2022 and January 2026.

REGENXBIO faces class action lawsuit alleging securities violations over failure to disclose adverse information about RGX-111 before FDA clinical hold.

REGENXBIO faces securities fraud lawsuit for allegedly making false statements about RGX-111 safety while withholding adverse trial data from investors between February 2022 and January 2026.

REGENXBIO faces securities lawsuit for allegedly misleading investors about RGX-111 gene therapy safety concerns. FDA imposed clinical hold after trial participant developed CNS tumor.

Law firm sues REGENXBIO for allegedly hiding safety concerns about gene therapy RGX-111. Stock dropped 17.8% after FDA clinical hold due to tumor in trial participant.